Brief: Calliditas Announces Positive Nefigard Open Label Extension Results
24/04/2024 07:44
April 24 (Reuters) - Calliditas Therapeutics AB
CALTX.ST :
* CALLIDITAS ANNOUNCES POSITIVE NEFIGARD OPEN LABEL
EXTENSION
RESULTS
* STUDY TO PHASE 3 NEFIGARD STUDY SHOWED A TREATMENT
RESPONSE
CONSISTENT WITH NEFIGARD STUDY
Source text for Eikon: ID:nWkrKy8Mk
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations